Special Issue

Early Diagnosis and Public Health and Ethics Issues

Message from the Guest Editors

Public health authorities and international bodies are confronted with the need to diagnose the risk of disease early and to take prevention and treatment measures as quickly as possible, regardless of whether it is an infectious or non-infectious pathology; the use of current medicine and precision medicine for diagnosing diseases is not only an objective of specialists in different fields of curative medicine but also for those in public health. The systematic approach of biomarkers can increase the accuracy of analyses, including in the case of population cohorts, the identification of risk factors, and, therefore, the implicitly of disease risk models, in parallel with the use of modern treatment methods, much cheaper and more accessible. In this Special Issue, we invite manuscripts that address the correlation of current information, public health, and clinical research objectives with modern methods of diagnosis and treatment, and the systematization of information from the perspective of ethics and public health.

Guest Editors

Dr. Monica Florescu

Faculty of Medicine, Transilvania University of Brasov, 40268 Brasov, Romania

Prof. Dr. Rogozea Liliana Marcela

Faculty of Medicine, Transilvania University of Brasov, 500036 Brasov, Romania

Deadline for manuscript submissions

closed (31 July 2021)



Medicines

an Open Access Journal by MDPI

Indexed in PubMed



mdpi.com/si/54352

Medicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
medicines@mdpi.com

mdpi.com/journal/medicines





Medicines

an Open Access Journal by MDPI

Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Medicines (ISSN 2305-6320) is an international, peer-reviewed, and open-access journal aimed at disseminating cutting-edge research in the field of drug discovery and clinical application. It publishes original research papers, research communications, letters, and systematic reviews. The contents of the papers handled are manufacture of new drugs, exploration of drug-delivery systems, therapeutic effect, action mechanism, and their modulation by intrinsic and extrinsic factors. We look forward to handling your contributions in the very near future.

Editor-in-Chief

Prof. Dr. Hiroshi Sakagami

Meikai University Research Institute of Odontology (M-RIO), 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within PubMed, PMC, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 45 days after submission; acceptance to publication is undertaken in 5.7 days (median values for papers published in this journal in the first half of 2025).

